Trial Profile

A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabocemagene autoficel (Primary)
Indications Epidermolysis bullosa dystrophica
Focus Registrational; Therapeutic Use
Acronyms DEFI-RDEB
Sponsors Fibrocell Science; Fibrocell Technologies

Most Recent Events

10 Aug 2022 Planned primary completion date changed from 1 Apr 2023 to 1 Feb 2023.
10 Aug 2022 Status changed from recruiting to active, no longer recruiting.
25 May 2022 According to a Castle Creek Biosciences media release, the financing is expected to provide sufficient capital for the company's completion of a Phase 3 study

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com